Efgartigimod
argenx
['ct041']
catherine broome from georgetown presenting a well-designed study of efgartigimod (fcrn inhibitor) in #itp in the #ash22 plenary session. a difficult trial but the primary endpoint was met with higher remissions and duration of control. 
Clinical Haematologist, marrow transplanter. Past President World WMDA and WBMT. Editor-in-Chief Internal Medicine Journal.